SCHEMBL10150484

SCHEMBL10150484

CC(=O)OC1CCCC2(CCCCC2)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.39
CHRM3 P20309 3/20 0.35
CYP3A4 P08684 2/20 0.35
TDP1 Q9NUW8 1/20 0.34
CYP2C9 P11712 1/20 0.34
EPHX1 P07099 2/20 0.33
HTT P42858 1/20 0.33
APOBEC3A P31941 1/20 0.33
CTDSP1 Q9GZU7 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.31
KMT2A Q03164 1/20 0.31
CHRM2 P08172 2/20 0.31
CHRM4 P08173 2/20 0.31
CHRM5 P08912 2/20 0.31
CHRM1 P11229 2/20 0.31
NAAA Q02083 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20798246 0.78 CYP3A4 (0.35) CYP2C19CHRM3CYP3A4TDP1CYP2C9
SCHEMBL10691591 0.76 CYP2C19 (0.36) CYP2C19CHRM3CYP3A4TDP1CYP2C9
SCHEMBL13219625 0.76 CYP2C19 (0.36) CYP2C19CHRM3EPHX1HTTCHRM2
SCHEMBL15958790 0.76 CYP2C19 (0.47) CYP2C19CYP3A4TDP1CYP2C9EPHX1
SCHEMBL15704501 0.76 CYP2C19 (0.47) CYP2C19CYP3A4TDP1CYP2C9EPHX1
SCHEMBL14887383 0.76 CYP2C19 (0.47) CYP2C19CYP3A4TDP1CYP2C9EPHX1
SCHEMBL19687800 0.76 CYP2C19 (0.47) CYP2C19CYP3A4TDP1CYP2C9EPHX1
SCHEMBL15427312 0.76 CYP2C19 (0.47) CYP2C19CYP3A4TDP1CYP2C9EPHX1
SCHEMBL4072779 0.76 CHRM3 (0.36) CYP2C19CHRM3
SCHEMBL23018499 0.75 EPHX1 (0.52) CYP2C19CHRM3EPHX1HTTCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same CYC1, UQCRB, CBR1 CYP2C19 37/4885CHRM3 263/4885CYP3A4 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.